scholarly journals Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Thi Hoa Nguyen ◽  
Van Hung Nguyen ◽  
Thanh Long Nguyen ◽  
Cai Qiuyin ◽  
Thi Huyen Phung
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Recurrent Breast Cancer ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Tissue Samples ◽  
Conversion Rates ◽  
Recurrent Breast

Background. Obtaining tumor specimens and re-evaluating targeted markers is recommended, if possible, in breast cancer patients who relapsed after curative treatment. The biomarker status changes in rebiopsied tumors have been demonstrated to have considerable clinical implications. Objectives. To identify the changes of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status between the primary and recurrent lesions. Materials and Methods. We conducted a study among 67 patients with recurrent breast cancer, recruited from January 2014 to September 2018 in the Vietnam National Cancer Hospital to compare ER, PR, and HER2 status between the primary and recurrent lesions. For each patient, a specimen of their primary tumor and another specimen of recurrent lesions underwent pathological assessment. Immunohistochemistry (IHC) was performed to determine ER, PR, and HER2 status in both specimens. Results. Biomarker status conversion rates (in both directions) between primary and recurrent tumors were 26.9% for ER, 38.8% for PR, and 22.4% for HER2. Overall, IHC subtypes (hormone receptor positive, HER2 amplified, and triple-negative) changed in 25 out of 67 (37.3%) cases. Conversion rates were not statistically significantly different between patients with different recurrent sites and times of recurrence. Eight out of 13 initially triple-negative patients (61.5%) had a change to positive status of either ER, PR, or HER2. Conclusion. A substantial discordance in ER, PR, and HER2 status were observed between primary breast cancer tissues and recurrent lesions. Rebiopsy could bring new therapeutic opportunities in the management of patients with recurrent breast cancer.

scholarly journals Serum prolactin responses to TRH in recurrent breast cancer patients.

1979 ◽  
Vol 26 (1) ◽  
pp. 141-145 ◽  
Author(s):  
MICHIO MIYAZAKI ◽  
KAZUHIKO YASUMURA ◽  
SATOSHI II ◽  
YASUAKI TAKATA ◽  
TOSHIAKI KAMI
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Recurrent Breast Cancer ◽  
Serum Prolactin ◽  
Breast Cancer Patients ◽  
Recurrent Breast

scholarly journals Clinical and dosimetric evaluation of recurrent breast cancer patients treated with hyperthermia and radiation

2019 ◽  
Vol 36 (1) ◽  
pp. 985-991 ◽  
Author(s):  
Sharvari Dharmaiah ◽  
Johnathan Zeng ◽  
Vinay S. Rao ◽  
Zi Ouyang ◽  
Tianjun Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Recurrent Breast Cancer ◽  
Breast Cancer Patients ◽  
Recurrent Breast

Changing ER, PgR, and HER2 status between primary and recurrent breast cancer.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 92-92 ◽  
Author(s):  
Akiko Matsumoto ◽  
Maiko Takahashi ◽  
Tetsu Hayashida ◽  
Shigemichi Hirose ◽  
Hiromitsu Jinno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Biological Markers ◽  
Distant Metastases ◽  
Recurrent Breast Cancer ◽  
University Hospital ◽  
Her2 Status ◽  
Fish Analysis ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Recurrent Breast

92 Background: Estrogen receptor (ER), progesterone receptor (PgR), and HER2 status are important biological markers for making decisions about breast cancer treatments. Although changes of hormone receptor (HR) and HER2 status with recurrence of breast cancer are clinically experienced, the frequency of discordance and clinical significance are still unknown. Thus, we investigated ER, PgR, and HER2 status with primary tumors and recurrent lesions, and assessed discordance rates and prognosis. Methods: We retrospectively identified recurrent breast cancer patients who had biopsies or resections of recurrent lesions between January 2007 to April 2012 at Keio University Hospital. HR status was assessed by immunohistochemistry (IHC) and determined using the Allred score. HR status was defined as positive when score was 3 and more. HER2 status was assessed by IHC and fluorescence in situ hybridization (FISH) analysis. We defined HER2 positivity as 3+ staining intensity by IHC or the presence of HER2 gene amplification by FISH. Results: Among 32 recurrences, 40% (13) were loco-regional recurrences (LLR) and 60% (19) were distant metastases (DM) (lung 14; liver 3; brain 1; pleura 1). Discordance rates in ER, PgR and HER2 status between the primary tumors and the recurrence lesions were 12.5%, 31.3%, and 13.8%, respectively. The most common change was loss of PgR. Changings from negative to positive in ER, PgR and HER2 status were found in 6.3%, 3.1%, and 3.4% of the patients, respectively. All gains were found in distant metastases. Discordance in ER and HER2 were more common in DM (15.8% and 17.6%) comparing with LRR (7.7% and 8.3%). Loss of HR status was not associated with a shorter time to progression (TTP) (ER: 19.3 vs. 8.5 months, p=0.185; PgR: 4.4 vs. 11.5 months, p=0.907). Patients with discordant HER2 status had significantly shorter TTP than with concordant status (0.9 vs. 11.5 months, p=0.012). Conclusions: Discordance of biological markers between primary and recurrent breast cancers were seen in 10-30%. Although HR discordance was not associated with prognosis, patients with HER2 discordance had poorer TTP. Tissue confirmation should be considered for making effective treatment decisions in recurrent breast cancer.

Seeing results: Outcomes from offering breast cancer survivorship care for more than 10 years.

2018 ◽  
Vol 36 (7_suppl) ◽  
pp. 32-32
Author(s):  
Andrew Joseph Ward ◽  
Jillian Lloyd ◽  
Emily Pospiech ◽  
Cystal Wheelon ◽  
Amila Orucevic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Medical Center ◽  
Recurrent Breast Cancer ◽  
Survivorship Care ◽  
Breast Cancer Patients ◽  
Tumor Registry ◽  
Time To Recurrence ◽  
Recurrent Breast ◽  
Disease Specific

32 Background: The University of Tennessee Medical Center (UTMCK), Knoxville Tennessee is the region’s sole academic medical center. Annually, 3000 new patients are seen within the Cancer Institute (CI) of UTMCK, and over 13% are breast cancer patients. Under the leadership of our director, Surgical Oncologist Dr. John L. Bell, survivorship care has been offered to these patients for almost twenty years. This combination has created a unique opportunity for us to look at long term results of offering disease-specific survivorship care, and what effect it has made upon detection of recurrence. Methods: Tumor registry data was utilized to examine the influence of survivorship care upon detection of recurrence. All patients treated from 1999 – 2015 with a diagnosis of recurrent breast cancer were selected out of the tumor registry. These patients were then stratified by time to recurrence, and mean, median, and range were calculated in time to recurrence (TR) by month. Results: A total of 223 patients with recurrent breast cancer were identified in our tumor registry out of 4422 total breast cancer patients treated by UTMCK from 1999 – 2015, recurrence rate of 5.04%. The mean TR for this cohort was 43.9 months. The median TR was 33 months, and the range of TR varied from 4 months to 166 months. All patients were followed for a minimum of five years following their diagnosis, and by 60 months, 73.99% of all recurrences were identified. Conclusions: Offering disease specific survivorship care to breast cancer patients is beneficial to both patients and our institution. When recurrence is diagnosed, survivorship care is valuable by helping to identify these cases as early as possible, to get patients back into active treatment sooner in the disease process. We have demonstrated that this is not a recent phenomenon reflective of current practice changes and accreditation requirements, and have validated this with our institution’s long history of providing survivorship care services for breast cancer patients dating back to the last century.

Abstract 4138: Immunological profile of metastatic or recurrent breast cancer patients

2016 ◽  
Author(s):  
Shigeru Imoto ◽  
Takayuki Ueno ◽  
Hirotsugu Isaka ◽  
Hiroki Ito ◽  
Kaisuke Miyamoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Recurrent Breast Cancer ◽  
Breast Cancer Patients ◽  
Immunological Profile ◽  
Recurrent Breast
Sign in / Sign up

Export Citation Format

Share Document